<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF-alpha) is expressed in the ischemic brain; however, its precise role is not fully understood </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the effect of the dimeric form of the type I soluble TNF receptor linked to <z:chebi fb="1" ids="46793">polyethylene glycol</z:chebi> (TNFbp) on focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in mice using a permanent middle cerebral <z:mp ids='MP_0006134'>arterial occlusion</z:mp> (MCAO) model </plain></SENT>
<SENT sid="2" pm="."><plain>TNFbp was applied topically, intravenously, or intraperitoneally </plain></SENT>
<SENT sid="3" pm="."><plain>TNFbp binds and inhibits TNF-alpha </plain></SENT>
<SENT sid="4" pm="."><plain>The volume of cortical ischemic lesions was measured by means of 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> 24 h after MCAO </plain></SENT>
<SENT sid="5" pm="."><plain>TNFbp produced a significant reduction in the cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume of vehicle-treated animals (p &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>The reduction in the volume of brain damage was 26% in animals that received 3 mg/kg of TNFbp topically </plain></SENT>
<SENT sid="7" pm="."><plain>Further analysis of TNF-alpha inhibition following <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> is indicated </plain></SENT>
</text></document>